{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Decitabine+20+mg%2Fm%C2%B2%2Fday+for+5+days",
    "query": {
      "intervention": "Decitabine 20 mg/m²/day for 5 days"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 27,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Decitabine+20+mg%2Fm%C2%B2%2Fday+for+5+days&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T02:13:59.389Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02343939",
      "title": "Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Entospletinib",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 148,
      "start_date": "2015-07-01",
      "completion_date": "2019-02-21",
      "has_results": true,
      "last_update_posted_date": "2019-11-15",
      "last_synced_at": "2026-10-10T02:13:59.389Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Maywood, Illinois + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02343939"
    },
    {
      "nct_id": "NCT00398983",
      "title": "Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2006-08",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2013-03-04",
      "last_synced_at": "2026-10-10T02:13:59.389Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00398983"
    },
    {
      "nct_id": "NCT00903760",
      "title": "Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Clofarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2010-01",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2018-11-15",
      "last_synced_at": "2026-10-10T02:13:59.389Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00903760"
    },
    {
      "nct_id": "NCT02996474",
      "title": "Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 10,
      "start_date": "2016-12-16",
      "completion_date": "2019-04-02",
      "has_results": true,
      "last_update_posted_date": "2022-12-28",
      "last_synced_at": "2026-10-10T02:13:59.389Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02996474"
    },
    {
      "nct_id": "NCT00414310",
      "title": "Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndrome",
        "Acute Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Valproic Acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 153,
      "start_date": "2006-12",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2019-05-21",
      "last_synced_at": "2026-10-10T02:13:59.389Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00414310"
    },
    {
      "nct_id": "NCT00358644",
      "title": "Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2005-03",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2013-05-20",
      "last_synced_at": "2026-10-10T02:13:59.389Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Los Angeles, California • St Louis, Missouri",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00358644"
    },
    {
      "nct_id": "NCT04172844",
      "title": "Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Pevonedistat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2020-01-13",
      "completion_date": "2022-02-27",
      "has_results": false,
      "last_update_posted_date": "2024-06-04",
      "last_synced_at": "2026-10-10T02:13:59.389Z",
      "location_count": 2,
      "location_summary": "Rochester, Minnesota • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04172844"
    },
    {
      "nct_id": "NCT03941964",
      "title": "A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2019-08-15",
      "completion_date": "2022-03-14",
      "has_results": true,
      "last_update_posted_date": "2023-03-20",
      "last_synced_at": "2026-10-10T02:13:59.389Z",
      "location_count": 16,
      "location_summary": "Tempe, Arizona • Denver, Colorado • Lone Tree, Colorado + 12 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03941964"
    },
    {
      "nct_id": "NCT02348489",
      "title": "SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Leukemia, Myeloid, Acute"
      ],
      "interventions": [
        {
          "name": "SGI-110 (guadecitabine)",
          "type": "DRUG"
        },
        {
          "name": "Treatment Choice",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astex Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 815,
      "start_date": "2015-03-19",
      "completion_date": "2019-06-17",
      "has_results": true,
      "last_update_posted_date": "2024-08-27",
      "last_synced_at": "2026-10-10T02:13:59.389Z",
      "location_count": 23,
      "location_summary": "Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 18 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02348489"
    },
    {
      "nct_id": "NCT02103478",
      "title": "Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndrome",
        "MDS"
      ],
      "interventions": [
        {
          "name": "ASTX727 Dose Escalation",
          "type": "DRUG"
        },
        {
          "name": "ASTX727 Dose Confirmation",
          "type": "DRUG"
        },
        {
          "name": "ASTX727 Fixed-Dose Combination",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astex Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2014-10-28",
      "completion_date": "2019-12-04",
      "has_results": true,
      "last_update_posted_date": "2024-08-27",
      "last_synced_at": "2026-10-10T02:13:59.389Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02103478"
    }
  ]
}